Navigation Links
InfraReDx's LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
Date:3/10/2010

BURLINGTON, Mass., March 10 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology (ACC). The meeting, named ACC.10 and i2 Summit, is being held from March 14 – 16, 2010 at the Georgia World Congress Center in Atlanta.  In addition to several oral presentations featuring LipiScan, InfraReDx has organized a "Meet the Experts" series of discussions at the Company's booth (#254) in which leading cardiologists will highlight LipiScan's capabilities in identifying and characterizing lipid core (fatty) plaque.

InfraReDx's LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be "vulnerable plaque" that can rupture and form dangerous blood clots leading to coronary thrombosis. LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.

"One of the biggest challenges facing interventional cardiologists today is the ability to detect vulnerable coronary and fatty plaques," said Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital. "As a result of improved imaging and diagnostic capabilities, however, physicians can now be armed with that information and are able to make important advances and improvements in patient care. This year's ACC meeting provides us with a great opportunity to interact with our colleagues, share key learnings and discuss important steps forward."

"We are pleased to be working so closely with these world renowned cardiology experts and leaders as they strive to improve patient care and we advance our LipiScan coronary imaging system," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "Through our close collaborations with these physicians and specialists, we are continuing to increase our working knowledge, enhance our LipiScan system and, ultimately, to significantly improve the imaging capabilities for interventional cardiologists and their patients. We are looking forward to a productive conference and many lively discussions at our booth about advancing the current standard of cardiac care."

The schedule of scientific sessions and "Meet the Experts" discussions to feature LipiScan is as follows.

ACC Scientific Sessions Highlighting LipiScan™ Coronary Imaging System:

Sunday, March 14:

8:00 a.m.9:30 a.m., Session #2092, Room B310

Session title: Imaging and Vulnerable Plaque

Presentation title: Association of Large Lipid Core Plaque Detected by Near Infrared Spectroscopy with Post Percutaneous Coronary Intervention Myocardial Infarction

Presenter: Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital

Tuesday, March 16

10:30 a.m. – Noon, Session #2629, Room B310

Session title: Vulnerable Plaque Update

Presentation title: Near-Infrared Spectroscopy

Presenter: James Goldstein, M.D., director of research and education, Division of Cardiology, William Beaumont Hospital

InfraReDx "Meet The Experts" series:

Sunday, March 14:

9:30 a.m.10:30 a.m., Exhibit Hall: Morning Break

"Increased Lipid Core Plaque in Women Undergoing Stenting"

Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Noon – 1:00 p.m., Exhibit Hall: ACC Lunch & Learn

"Lipid Core Plaque Modification"

Expert: Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital

1:00 p.m.2:00 p.m., Exhibit Hall: ACC Lunch & Learn

"LipiScan™ Clinical Experience; Identification of Bifurcation Lesions at Risk of Compromise"

Expert: Giora Weisz, M.D., director of clinical research, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center

3:30 p.m.4:30 p.m., Exhibit Hall: Poster Hour

"Pick the Peri-Stenting MI"

Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Monday, March 15:

9:30 a.m.10:30 a.m., InfraReDx Booth # 254

"Multi-Modality Imaging"

Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Noon – 1:00 p.m., InfraReDx Booth #254

"Stent Length Placement & Distal Embolization"

Expert: James Goldstein, M.D., director of research and education, Division of Cardiology, William Beaumont Hospital

1:00 p.m.2:00 p.m., InfraReDx Booth #254

"Peri-Stenting MI"

Expert: Emmanouil S. Brilakis, M.D., Ph.D., director of the cardiac catheterization laboratory, Dallas VA Medical Center

3:30 p.m.4:30 p.m., InfraReDx Booth #254

"PROSPECT Trial and the Vulnerable Plaque"

Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

Tuesday, March 16

9:30 a.m.10:30 a.m., InfraReDx Booth #254

"Vulnerable Blood & Vulnerable Plaque; Coagulation Profiling & Plaque Morphology

Characterization"

Expert:  Paul A. Gurbel, M.D., director of cardiovascular research, Center for Thrombosis Research, Sinai Hospital of Baltimore

Noon – 1:00 p.m., InfraReDx Booth # 254

"Advances in Intra-coronary Imaging in the Past Year - NIR, IVUS, OCT and Others"

Expert: James E. Muller, M.D., founder and chief executive officer of InfraReDx

About ACC.10 and i2 Summit 2010

The Annual Scientific Session of the American College of Cardiology (ACC) is the largest and foremost cardiovascular meeting, offering attainable, reliable and applicable learning solutions that help cardiovascular professionals turn knowledge into practice that saves and improves lives. The Annual Scientific Session delivers timely medical education leveraging innovative need-based learning methods. Together, ACC.10 and i2 Summit 2010 embody the College's vision of building meetings with innovative solutions that assist the faculty to teach and audiences to learn.  For more information, visit http://acc10.acc.org/Pages/ACC2010Home.aspx.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.  

    
    
    Contacts: 
    Media:
    Keri Mattox
    Pure Communications, Inc.
    215.791.0105
    keri@purecommunicationsinc.com
    
    Company:
    Jim Dillon
    Vice President of Sales and Marketing
    781.345.9679
    jdillon@infraredx.com
    

SOURCE InfraReDx, Inc.

Back to top

RELATED LINKS
http://www.infraredx.com

'/>"/>

SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
3. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
4. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease
9. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Corporation ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), ... its financial results for the second quarter of fiscal 2016 (three ... Financial Results for the Second Quarter of ... Revenue for the second quarter of fiscal 2016 was $4.5 ... Cash receipts from customers for the second quarter of fiscal 2016 ...
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... February 9, 2016 QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QGEN ; Frankfurt ... 10x Genomics to develop and promote comprehensive solutions ... --> QIAGEN N.V. (NASDAQ: QGEN ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... Carefree, AZ (PRWEB) , ... February 10, 2016 , ... ... coach in new book , Pioneering book "Better with Age: The Ultimate Guide to ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine ... provide a solution that ensures the integrity of biological samples while operating at ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has been ... still face a lot of restrictions as to where they can smoke pot. ... use” and that cannabis “may not be consumed openly or publicly.” , Given the ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Face and Body Specialists are delighted to welcome a new addition to their ... Face and Body Specialists as a nurse practitioner performing cosmetic procedures ...
Breaking Medicine News(10 mins):